Ocugen, Inc. has pushed its decision on a major equity expansion to late October, leaving investors to weigh a proposal that would add 250 million shares to the company's authorized common stock. The move follows a series of adjournments that have stretched the voting process across several weeks, raising questions about the level of shareholder support for the dilution.
The company filed a Form 8-K with the U.S. Securities and Exchange Commission on October 5, 2026, detailing the status of its Special Meeting of Stockholders. The meeting, originally convened virtually, was reconvened on that date after having been adjourned on September 21, 2026. The September adjournment was limited to Proposal 1, which seeks to amend the Sixth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, with a par value of $0.01 per share, by 250 million units.
At the October 5 reconvened meeting, management decided to adjourn the proceedings again, specifically regarding Proposal 1. The stated purpose of this second delay is to provide additional time for stockholders to consider and vote on the matter. The new date for the Adjourned Meeting is set for October 26, 2026, at 8:00 a.m. Eastern Time. The session will be held virtually via www.virtualshareholdermeeting.com/OCGN2026SM.
The record date for determining which stockholders are entitled to vote at the upcoming meeting remains July 27, 2026. This means that the pool of eligible voters has not changed despite the shift in the voting timeline. Ocugen noted that stockholders who have already submitted their proxies or cast their votes do not need to take further action if they intend to maintain their previous stance on Proposal 1.
The filing was signed by Shankar Musunuri, who serves as Chairman, Chief Executive Officer, and Co-Founder of Ocugen. The company is incorporated in Delaware and lists its common stock on The Nasdaq Capital Market under the ticker symbol OCGN. Its principal executive office is located at 11 Great Valley Parkway in Malvern, Pennsylvania.
The repeated adjournments highlight the complexity of securing shareholder approval for significant changes to capital structure. By extending the deadline to October 26, Ocugen aims to allow for more deliberation among its investor base before the final vote on the proposed increase in authorized shares.